| Title |
Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors |
| Description |
Phase I: To evaluate the safety and tolerability of GFH925 in subjects with KRAS G12C mutant advanced solid tumors and estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D).Phase II: To evaluate the efficacy of GFH925 in subjects with KRAS G12C mutant advanced non-small cell lung cancer (NSCLC). |
| Organism |
Homo sapiens |
| Data Type |
Other Type of Genomic Data |
| Data Accessibility |
Controlled-access |
| BioProject |
PRJCA013958 |
| Release Date |
2024-12-31 |
| Submitter |
bin min (bingo.min@innoventbio.com) |
| Organization |
Innovent Biologics (Suzhou) Co., Ltd. |
| Submission Date |
2022-12-19 |